Develop a novel odin therapeutic medical countermeasure capable of protecting against pneumonic unencapsulated Y. Pestis.
Ended Awarded Last action
- Contract number
- HT942524F0127
- Awardee
-
Eitr Biologics, Inc. UEI HX49LZLY32G5
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $499,896
Award facts
- Opportunity
-
- HT942523R0061 Solicitation number
- Contract value 100% obligated
- $499,896.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a $499,896 firm fixed-price delivery order to Eitr Biologics, Inc., a San Diego-based biotechnology company specializing in medical countermeasures and nanotherapeutics. The contract, awarded July 1, 2024, with completion targeted for June 30, 2025, calls for the development of a novel ODIN therapeutic medical countermeasure capable of protecting against pneumonic unencapsulated Yersinia pestis, the causative agent of plague. The work will be performed in San Diego, California, and no small business set-aside was used for this award.
This delivery order is issued under Eitr Biologics' existing Indefinite Delivery Vehicle contract with the Defense Health Agency, valued at $4.39 million through August 2028, which focuses on developing novel nanotherapeutics to combat biological threats with emphasis on pneumonic plague. The company has demonstrated specialized capabilities in this domain through previous Defense Health Agency-funded research on nanotherapeutic approaches targeting Yersinia pestis and antibody discovery platforms, positioning it as a key contributor to the agency's biological defense medical countermeasure development efforts.
Quick answers
Who was awarded contract HT942524F0127?
HT942524F0127 was awarded to Eitr Biologics, Inc. by Defense Health Agency (Department of Defense) on July 1, 2024.
How much is contract HT942524F0127 worth?
The government has obligated $499,896 on HT942524F0127.
Is contract HT942524F0127 an order under another contract?
Yes. HT942524F0127 is a delivery order under HT942523D0011, an indefinite delivery contract.
Was contract HT942524F0127 competed?
The extent of competition for HT942524F0127 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award